Abviva to receive patent for its new Mammastatin technology Abviva, Inc. , a biomedical organization engaged in the advancement and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2 2.267.095 within 12 weeks. The Mammastatin technology proceeds to increase its safety as evidenced by the granting of patents around its core technology. The Company is quite pleased with this see of patent to become granted and believes that the issuance of the many patents will allow Abviva to broaden internationally in years to come, said Barrett Evans, Abviva’s CEO.Glycoprotein-specific memory space CD4 and CD8 T-cell responses were better in magnitude at week 4 than at week 2 and greater in group 2 than in group 1 .16 cAd3 and Ad5 Serologic Assessment Background immunity might affect the response to virus-vectored vaccines. We assessed cAd3 neutralizing antibody titers in all individuals at baseline and 4 weeks after vaccination and compared them with antibody and T-cell responses . At baseline, reciprocal titers of anti-cAd3 neutralizing activity ranged from undetectable to 911.